Latest Regulatory News

The Reject Shop has announced a fully franked special dividend of $0.77 per share as part of its acquisition by Dollarama, boosting the total transaction consideration to $6.68 per share.

ASPI Isotopes Inc. has proposed a scheme to acquire all Renergen shares at a 41.3% premium, aiming to create a global critical materials powerhouse. The deal, subject to shareholder and regulatory approval, will delist Renergen from multiple exchanges.

Renergen Limited shareholders have received a detailed circular outlining ASP Isotopes Inc.'s firm intention to acquire the company through a scheme of arrangement, with a general meeting scheduled for 10 July 2025 to approve the deal.

NexGen Energy has secured regulatory approval for a significant infrastructure upgrade at its Rook I uranium project, setting the stage for expanded exploration and operational efficiency in 2025.

FireFly Metals Ltd has announced a flow-through share offer aiming to raise approximately A$11.2 million, targeting Canadian investors to fund regional exploration drilling. This offer complements a broader capital raising strategy to advance development at the Ming Mine and other key projects.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

PointsBet Holdings has secured Foreign Investment Review Board approval for MIXI Australia's proposed full acquisition, marking a key regulatory milestone in the takeover process.

BetMakers Technology Group has successfully raised $11.5 million through a share placement aimed at repaying debt and funding strategic growth initiatives, including a potential acquisition in Nevada.

Hazel Group Limited has temporarily paused trading of its securities on the ASX, signaling an impending announcement that investors will want to watch closely.

Hawsons Iron Ltd has been reinstated to ASX trading following an announcement of a proposed capital raising, signaling renewed investor interest.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.